Great Bay Bio Gained HK SME Innovative Award
Great Bay Bio awarded Merit Award for Innovative Hong Kong SME
[2019/12/18, Hong Kong] On Dec 18th, 2019, Great Bay Bio attends the award ceremony held by Hong Kong Greater China SME Alliance Association, and gained the Merit Award for HK SME Innovative Award. This fully presents the R&D innovative capability of Great Bay Bio, as Great Bay Bio has been continuously enhanced its innovative capability and strived to make global drug development much easier and simpler.
Hong Kong Greater China SME Alliance Association
The Hong Kong Greater China SME Alliance Association anticipates in the promotion of the future economic development of the small and medium enterprises in Hong Kong, in coordinate with the promotion by the Government in the Sino-HK development direction in the Greater Bay Area, actively liaising with the industrial and commercial organizations throughout Mainland China for the purpose of mutual exchange of technologies, providing a wilder vision and developing a co-operation relationship for the creation of collaborative business opportunities. In recent years, there are repeated results by virtue of the promotion in the mutual co-operation amongst the small and medium enterprises and assisting in the career development, to continue to seek more co-operation opportunities by taking advantage of the complimentary resources in both China and Hong Kong and to explore the development ideas between the small and medium enterprises in both China and Hong Kong.
HK SME Innovative Award 2019
The 4th HK SME Innovative Award aims to praise SMEs for their innovative spirit and outstanding performance. To promote the development of Greater Bay Area, the award has allowed all companies in this area to join the contest to facilitate exchanges between Hong Kong and Mainland enterprises, boost their businesses and stimulate their breakthroughs in the future.
About Great Bay Bio
Headquartered in Hong Kong, GBB is a high-tech enterprise dedicated to applying artificial intelligence and other cutting-edge technologies to CMC (Chemistry, Manufacturing, Control) for development of biopharmaceuticals and other blue ocean bio-products (such as cell therapy), ultimately solving numerous pain points of CMC development, including high failure rates, long development timeline and high costs. Since the company’s establishment, it has obtained massive data from conventional biologics development in its 3100 m2 CMC facilities in Dongguan, PRC. With over RMB 300M investment, the facilities bolster advance equipment from world-renowned manufacturers. GBB has also successfully brought a number of biologic products to NDA stage, some of which are classified as national class I innovative drugs. Currently, the company has created the intelligent centralized database, where deep learning is being performed to create next generation AI-enabled CMC platforms. To learn more, please visit http://www.greatbay-bio.com.
PR Contact: Miss Liu